Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance
Open accessThe DOI matches its Crossref record; 311 of the 318 references it cites were found in a registry or an index.
Abstract
Resistance to targeted therapies is a complex and multifactorial process that culminates in the selection of a cancer clone with the ability to evade treatment. Chronic myeloid leukemia (CML) was the first malignancy recognized to be associated with a genetic alteration, the t(9;22)(q34;q11). This translocation originates the BCR-ABL1 fusion gene, encoding the cytoplasmic chimeric BCR-ABL1 protein that displays an abnormally high tyrosine kinase activity. Although the vast majority of patients with CML respond to Imatinib, a tyrosine kinase inhibitor (TKI), resistance might occur either de novo or during treatment. In CML, the TKI resistance mechanisms are usually subdivided into BCR-ABL1-dependent and independent mechanisms. Furthermore, patients’ compliance/adherence to therapy is critical to CML management. Techniques with enhanced sensitivity like NGS and dPCR, the use of artificial intelligence (AI) techniques, and the development of mathematical modeling and computational prediction methods could reveal the underlying mechanisms of drug resistance and facilitate the design of more effective treatment strategies for improving drug efficacy in CML patients. Here we review the molecular mechanisms and other factors involved in resistance to TKIs in CML and the new methodologies to access these mechanisms, and the therapeutic approaches to circumvent TKI resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“One cluster summarized the concepts related to the development of resistance to chemotherapy drugs, rendering the treatment ineffective in inhibiting cancer cell proliferation or inducing cell death. This discovery has been repeatedly validated through experimental results from BCR-ABL kinase-independent pathways that promote CML cell survival and proliferation, bypassing TKI inhibition [84, 85].”
From GOLDEN fusion: a graph-oriented learning with domain-embedding network fusion for generating super gene sets in functional genomics (2026) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“Multiple factors, not necessarily mutually exclusive, can contribute to TKI resistance [46].”
From 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia (2025) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–311 of 311
Nilotinib in the Treatment of Chronic Myeloid Leukemia
Sacha, T., & Saglio, G. N. (2018) · Future Oncology · doi:10.2217/fon-2018-0468 · Cited by 54
Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
Cumbo, C., Anelli, L., Specchia, G., & Albano, F. (2020) · Cancer Management and Research · doi:10.2147/cmar.s232752 · Cited by 54
Lu, Z., Xu, N., He, B., Pan, C., Lan, Y., Zhou, H., & Liu, X. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0512-6 · Cited by 53
Rothe, K., Babaian, A., Nakamichi, N., Chen, M., Chafe, S. C., Watanabe, A., Forrest, D. L., Mager, D. L., Eaves, C. J., Dedhar, S., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.04.005 · Cited by 53
Cortes, J. E., Jabbour, E. J., Daley, G. Q., O'Brien, S. M., Verstovšek, S., Ferrajoli, A., Koller, C. A., Zhu, Y., Statkevich, P., & Kantarjian, H. M. (2007) · Cancer · doi:10.1002/cncr.22901 · Cited by 52
Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors
Yaghmaie, M., & Yeung, C. C. S. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00543-7 · Cited by 51
Słupianek, A., Falinski, R., Znojek, P., Stokłosa, T., Flis, S., Doneddu, V., Pytel, D., Synowiec, E., Błasiak, J., Bellacosa, A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.294 · Cited by 50
Genetic Mechanisms of Chronic Myeloid Leukemia Blastic Transformation
Skórski, T. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0114-5 · Cited by 49
Šrůtová, K., Čuřík, N., Burda, P., Savvulidi, F. G., Silvestri, G., Trotta, R., Klamová, H., Pecherková, P., Sovová, Ž., Koblihova, J., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.193086 · Cited by 49
de Lima, L. T., Vivona, D., Bueno, C. T., Hirata, R. D. C., Hirata, M. H., Luchessi, A. D., de Castro, F. A., Chauffaille, M. D. L. L. F., Zanichelli, M. A., CHIATTONE, C. S., et al. (2014) · Medical Oncology · doi:10.1007/s12032-014-0851-5 · Cited by 46
Targeting Translation of mRNA as a Therapeutic Strategy in Cancer
Pal, I., Safari, M., Jovanovic, M., Bates, S. E., & Deng, C. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00530-y · Cited by 46
Cortes, J. E., Quintás‐Cardama, A., Garcia‐Manero, G., O'Brien, S. M., Jones, D. M., Faderl, S. H., Ebarb, T., Giles, F. J., Thomas, D. A., & Kantarjian, H. M. (2007) · Cancer · doi:10.1002/cncr.23006 · Cited by 45
ApoptomiRs expression modulated by BCR–ABL is linked to CML progression and imatinib resistance
Ferreira, A. F., Moura, L. G., Tojal, I., Ambrósio, L., Simões, B. P., Hamerschlak, N., Călin, G. A., Ivan, C., Covas, D. T., Kashima, S. H., et al. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.02.008 · Cited by 45
Ruvolo, P. P., Zhou, L., Watt, J. C., Ruvolo, V. R., Burks, J. K., Jiffar, T., Kornblau, S. M., Konopleva, M. Y., & Andreeff, M. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23090 · Cited by 45
Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells
Baykal, S., Açıkgöz, E., Yavuz, A. S., Geyik, Ö. G., Ateş, H., Sezerman, O. U., Özsan, G. H., & Yüce, Z. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229104 · Cited by 45
Sasaki, K., Jabbour, E. J., Ravandi, F., Konopleva, M. Y., Borthakur, G. M., Wierda, W. G., Daver, N. G., Takahashi, K., Naqvi, K. Z., Dinardo, C. D., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.26047 · Cited by 45
Signal Transduction in the Chronic Leukemias: Implications for Targeted Therapies
Ahmed, W. B., & Etten, R. A. V. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0150-1 · Cited by 44
Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay
Chung, H., Hur, M., Yoon, S., Hwang, K., Lim, H. S., Kim, H., Moon, H., & Yun, Y. (2019) · Annals of Laboratory Medicine · doi:10.3343/alm.2020.40.1.72 · Cited by 44
García‐Gutiérrez, V., Luna, A., Alonso‐Domínguez, J. M., Estrada, N., Boqué, C., Xicoy, B., Giraldo, P., Angona, A., Álvarez‐Larrán, A., Sanchez-Guijo, F. M., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00420-8 · Cited by 44
Mu, H., Zhu, X., Jia, H., Zhou, L., & Liu, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.643382 · Cited by 43
Nie, Z.-Y., Yao, M., Yang, Z., Yang, L., Liu, X.-J., Yu, J. Q., Ma, Y., Zhang, N., Zhang, X., Liu, M., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1502-7 · Cited by 42
Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
Soverini, S., Bernardi, S., & Galimberti, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123865 · Cited by 42
Berman, E., Jhanwar, S., Hedvat, C., Arcila, M. E., Wahab, O. A., Levine, R., Maloy, M., Ma, W., & Albitar, M. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.08.006 · Cited by 41
Eadie, L. N., Hughes, T. P., & White, D. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161470 · Cited by 41
Pleyer, L., Burgstaller, S., Stauder, R., Girschikofsky, M., Sill, H., Schlick, K., Thaler, J., Halter, B., Machherndl-Spandl, S., Zebisch, A., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0263-4 · Cited by 40
Al-Dewik, N. I. E., Morsi, H. M., Samara, M. M., Ghasoub, R. S., Gnanam, C. C., Bhaskaran, S. K., Nashwan, A. J., Al‐Jurf, R., Ismail, M. A., Alsharshani, M., et al. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s32822 · Cited by 40
Kumar, R., Pereira, R. S., Zanetti, C., Minciacchi, V. R., Merten, M., Meister, M., Niemann, J., Dietz, M. S., Rüssel, N., Schnütgen, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0866-1 · Cited by 40
Hauser, R. G., Esserman, D., Beste, L. A., Ong, S. Y., Colomb, D. G., Bhargava, A., Wadia, R. J., & Rose, M. G. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab086 · Cited by 39
Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia
Mukaida, N., Tanabe, Y., & Baba, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081824 · Cited by 39
DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia
Popp, H. D., Kohl, V., Naumann, N., Flach, J., Brendel, S., Kleiner, H., Weiß, C., Seifarth, W., Saußele, S., Hofmann, W., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041177 · Cited by 39
A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia
de Lavallade, H., Finetti, P., Carbuccia, N., Khorashad, J. S., Charbonnier, A., Foroni, L., Apperley, J. F., Vey, N., Bertucci, F., Birnbaum, D., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.09.026 · Cited by 38
Jiang, Z., Zhao, X., Takahashi, N., Angelini, S., Dubashi, B., Sun, L., & Xu, P. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0103 · Cited by 38
Ripperger, A., & Benndorf, R. A. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.02.011 · Cited by 37
Megías‐Vericat, J. E., Montesinos, P., Herrero, M. J., Moscardó, F., Bosó, V., Rojas, L. E., Martínez‐Cuadrón, D., Hervás, D., Boluda, B., García-Robles, A. A., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1231405 · Cited by 37
MicroRNA signature refine response prediction in CML
Alves, R., Gonçalves, A. C., Jorge, J., Marques, G., Luís, D., Ribeiro, A. B., Freitas-Tavares, P., Oliveiros, B., Almeida, A. M., & Sarmento‐Ribeiro, A. B. (2019) · Scientific Reports · doi:10.1038/s41598-019-46132-9 · Cited by 37
Self-citationDeFilipp, Z. M., Ancheta, R. G., Liu, Y., Hu, Z., Gale, R. P., Snyder, D., Schouten, H. C., Kalaycio, M. E., Hildebrandt, G. C., Üstün, C., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.10.017 · Cited by 37
Skorski, T. (2011) · Leukemia & Lymphoma · doi:10.3109/10428194.2010.546912 · Cited by 36
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
Polillo, M., Galimberti, S., Baratè, C., Petrini, M., Danesi, R., & Paolo, A. D. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922811 · Cited by 36
Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update
Eşkazan, A. E., & Keskin, D. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717719851 · Cited by 36
Kaehler, M., & Cascorbi, I. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.696960 · Cited by 36
Salles, D. C., Mencalha, A. L., Ireno, I. C., Wiesmüller, L., & Abdelhay, E. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq216 · Cited by 35
Epigenetic dysregulation of hematopoietic stem cells and preleukemic state
Kunimoto, H., & Nakajima, H. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2257-6 · Cited by 32
Ivanova, E. S., Tatarskiy, V. V., Yastrebova, M. A., Khamidullina, A. I., Shunaev, A. V., Kalinina, A. A., Зейфман, А. А., Novikov, F. N., Dutikova, Y. V., Chilov, G. G., et al. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4801 · Cited by 32
Głowacki, S., Synowiec, E., Szwed, M., Toma, M. M., Skórski, T., & Śliwiński, T. (2021) · Biomolecules · doi:10.3390/biom11040610 · Cited by 32
Wolanin, K., Magalska, A., Kusio-Kobiałka, M., Podszywalow‐Bartnicka, P., Vejda, S., McKenna, S. L., Mosieniak, G., Sikora, E., & Piwocka, K. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0936 · Cited by 31
Vaidya, S., Ghosh, K., Shanmukhaiah, C., & Vundinti, B. R. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.08.034 · Cited by 30
Vaidya, S., Vundinti, B. R., Shanmukhaiah, C., Chakrabarti, P., & Ghosh, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0114828 · Cited by 30
Declaration of Bcr-Abl1 independence
Zhao, H., & Deininger, M. W. (2020) · Leukemia · doi:10.1038/s41375-020-01037-9 · Cited by 30
Eadie, L. N., Dang, P., Goyne, J. M., Hughes, T. P., & White, D. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192180 · Cited by 29
Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance
Singh, V. K., & Coumar, M. S. (2018) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557518666181017124854 · Cited by 28
Muselli, F., Peyron, J., & Mary, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225616 · Cited by 28
Drug transporters play a key role in the complex process of Imatinib resistance in vitro
Alves, R., Fonseca, A. R., Gonçalves, A. C., Ferreira-Teixeira, M., Lima, J., Abrantes, A. M., Alves, V., Rodrigues‐Santos, P., Jorge, L., Matoso, E., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.12.008 · Cited by 26
Self-citationDkhissi, F., Aggoune, D., Pontis, J., Sorel, N., Piccirilli, N., Corf, A. L., Guilhot, F., Chomel, J., Ait‐Si‐Ali, S., & Turhan, A. G. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.04.013 · Cited by 25
Vasconcelos, F. D. C., Scheiner, M. A. M., Moellmann‐Coelho, A., Mencalha, A. L., Renault, I. Z., Rumjanek, V. M., & Maia, R. C. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.10.005 · Cited by 24
Hassine, I. B., Gharbi, H., Soltani, I., Teber, M., Farrah, A., Othmen, H. B. H., Amouri, H., Bellâaj, H., lakhal, R. B., Romdhane, N. B., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3266-0 · Cited by 24
Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia
Alves, R., Gonçalves, A. C., Jorge, J., Alves, J., da Silva, A. A., Freitas-Tavares, P., Costa, N., Almeida, A. M., & Sarmento‐Ribeiro, A. B. (2019) · Medical Oncology · doi:10.1007/s12032-019-1253-5 · Cited by 24
Self-citationPKC‐β/Alox5 axis activation promotes Bcr‐Abl‐independent TKI‐resistance in chronic myeloid leukemia
Ma, D., Liu, P., Wang, P., Zhou, Z., Fang, Q., & Wang, J. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30301 · Cited by 24
MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
Harrach, S., Schmidt‐Lauber, C., Pap, T., Pavenstädt, H. J., Schlatter, E., Schmidt, E., Berdel, W. E., Schulze, U., Edemir, B., Jeromin, S., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.79 · Cited by 23
Makhtar, S. M., Husin, A., Baba, A. A., & Ankathil, R. (2018) · Journal of Genetics · doi:10.1007/s12041-018-0978-9 · Cited by 23
Zhan, J., Ma, J., & Zheng, Q. (2019) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2019.03.018 · Cited by 23
Lernoux, M., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113698 · Cited by 22
Rinaldetti, S. L., Pfirrmann, M., Manz, K. M., Guilhot, J., Dietz, C., Panagiotidis, P., Spieß, B., Seifarth, W., Fabarius, A. C., Müller, M. C., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.02.004 · Cited by 22
Inselmann, S., Wang, Y., Saußele, S., Fritz, L. V., Schütz, C., Huber, M., Liebler, S., Ernst, T., Cai, D., Botschek, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1477 · Cited by 22
Liu, X., Wang, G., Yan, X., Qiu, H., Min, P., Wu, M., Tang, C., Zhang, F., Tang, Q., Zhu, S., et al. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0351-6 · Cited by 22
Nieborowska-Skorska, M., Flis, S., & Skorski, T. (2014) · Leukemia · doi:10.1038/leu.2014.249 · Cited by 21
Banjar, H. R., Adelson, D. L., Brown, F., & Chaudhri, N. A. (2017) · BioMed Research International · doi:10.1155/2017/3587309 · Cited by 21
Deactylase inhibition in myeloproliferative neoplasms
Mithraprabhu, S., Grigoriadis, G., Khong, T. T., & Spencer, A. G. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9590-4 · Cited by 20
Lin, T.-Y., Chen, K., Liu, H.-J. E., Liu, A.-J., Wang, K.-L., & Shih, C.-M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156260 · Cited by 20
Subramaniam, A., Pattnayak, N. C., & Chakraborty, S. (2016) · Scientific Reports · doi:10.1038/srep32493 · Cited by 20
The research progress of circular RNAs in hematological malignancies
Ji, T., Chen, Q., Tao, S., Shi, Y., Chen, Y., Shen, L., Wang, C., & Yu, L. (2019) · Hematology · doi:10.1080/16078454.2019.1669924 · Cited by 20
Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia
Kwaśnik, P., & Giannopoulos, K. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080697 · Cited by 20
Błasiak, J., Hoser, G., Białkowska, J., Pawłowska, E., & Skórski, T. (2015) · BioResearch open access · doi:10.1089/biores.2015.0022 · Cited by 19
Bernardo, P. S., Lemos, L. G. T., de Moraes, G. N., & Maia, R. C. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100671 · Cited by 19
Stetka, J., Gurský, J., Velasquez, J. L., Mojzíková, R., Vyhlidalova, P., Vráblová, L., Bártek, J., & Divoký, V. (2020) · Cancers · doi:10.3390/cancers12040903 · Cited by 19
Structure, Function, and Resistance in Chronic Myeloid Leukemia
Radich, J. P. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.08.010 · Cited by 18
Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Martinelli, G., Iacobucci, I., Paolini, S., & Ottaviani, E. (2008) · PubMed · Cited by 18
Arroyo, M., Berral-González, A., Bueno-Fortes, S., Alonso‐López, D., & Rivas, J. D. L. (2020) · Biomolecules · doi:10.3390/biom10050667 · Cited by 18
Methylation status of RASSF1A in patients with chronic myeloid leukemia
Avramouli, A., Tsochas, S., Μανδαλά, Ε., Katodritou, E., Ιωάννου, Μ., Ritis, K., & Speletas, M. G. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.01.003 · Cited by 17
Rivas, J. D. L., Alonso‐López, D., & Arroyo, M. (2017) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2017.09.002 · Cited by 17
Marcé, S., Cortés, M., Zamora, L., Cabezón, M., Grau, J., Millá, F., & Feliú, E. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.04.007 · Cited by 16
Somatic mosaicism in chronic myeloid leukemia in remission
Mitani, K., Nagata, Y., Sasaki, K., Yoshida, K., Chiba, K., Tanaka, H., Shiraishi, Y., Miyano, S., Makishima, H., Nakamura, Y., et al. (2016) · Blood · doi:10.1182/blood-2016-06-723494 · Cited by 16
Immunotherapy of Chronic Myeloid Leukemia: Present State and Future Prospects
Vonka, V. (2010) · Immunotherapy · doi:10.2217/imt.10.2 · Cited by 16
Brown, J. T., Laosinchai-Wolf, W., Hedges, J. B., Watt, C. D., Deerlin, V. M. V., Fletcher, L., Branford, S., & Labourier, E. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.10 · Cited by 15
DNA damage response in imatinib resistant chronic myeloid leukemia K562 cells
Dinis, J., Silva, V. M. D. S., Gromicho, M., Martins, C., Laires, A., Tavares, P., Rendeiro, P., Torres, F., Rueff, J., & Rodrigues, A. S. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.681654 · Cited by 15
Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches
Cayssials, É., & Guilhot, F. (2017) · BioDrugs · doi:10.1007/s40259-017-0225-6 · Cited by 13
Brown, J. T., Beldorth, I., Laosinchai-Wolf, W., Fahey, M. E., Jefferson, K. L., Ruskin, A. K., Roth, J. J., Cai, L., Watt, C. D., Press, R. D., et al. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.03.002 · Cited by 13
Reff, M. J., Shillingburg, A., Shah, B., Elder, C. T., Prescott, H., & Kennerly-Shah, J. M. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219864640 · Cited by 13
Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review
Torres-Barrera, P., Mayani, H., & Chávez‐González, A. (2021) · Current Research in Translational Medicine · doi:10.1016/j.retram.2021.103295 · Cited by 13
Morozova, Е. V., Vlasova, Y. Y., Pryanishnikova, M. V., Lepik, K. V., & Afanasyev, B. V. (2015) · Biomarker Insights · doi:10.4137/bmi.s22438 · Cited by 12
Cayuela, J., Chomel, J., Coiteux, V., Dulucq, S., Escoffre‐Barbe, M., Etancelin, P., Étienne, G., Hayette, S., Millot, F., Nibourel, O., et al. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.05.011 · Cited by 11
The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia
Xu, H., Liu, J., Shen, N., Zhao, Z., Cui, J., Zhou, S., Jiang, L., Zhu, X., Tang, L. F. P., Liang, H., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1658098 · Cited by 11
Prinsloo, A., Pool, R., & van Niekerk, C. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1319 · Cited by 10
Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms
Cardoso, B. A., Ramos, T. L., Belo, H., Vilas‐Boas, F., Real, C., & Almeida, A. M. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.02.002 · Cited by 10
Self-citationYassine, F., Reljic, T., Moustafa, M. A., Iqbal, M., Murthy, H. S., Kumar, A., & Kharfan‐Dabaja, M. A. (2021) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2021.02.003 · Cited by 9
Chhikara, S., Sazawal, S., Seth, T., Chaubey, R., Singh, K., Sharma, R., Mishra, P. P., Mahapatra, M., & Saxena, R. (2017) · PubMed Central · doi:10.22034/apjcp.2017.18.8.2043 · Cited by 8
Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells
Okabe, S., Tauchi, T., Tanaka, Y., & Ohyashiki, K. (2016) · Blood · doi:10.1182/blood.v128.22.5428.5428 · Cited by 8
The roles of DNA epigenetics and clinical significance in Chronic Myeloid Leukemia: a review
Keramatinia, A., Ahadi, A., Akbari, M. E., Mohseny, M., Jarahi, A. M., Bahadorimonfared, A., Hashemi, M., Moradi, A., Mehrvar, N., Kazemi, E., et al. (2018) · Cellular and Molecular Biology · doi:10.14715/cmb/2018.64.9.9 · Cited by 7
Firatligil, B., Avcı, Ç. B., & Baran, Y. (2013) · PubMed · Cited by 6
Andrade, A. R., Leitão, D. D. S., Paz, I. P., Evangelista, T. R., de Mello, V. J., & Hamoy, M. (2019) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2018.09.006 · Cited by 6
Soverini, S., Martelli, M., Bavaro, L., Benedittis, C. D., Iurlo, A., Galimberti, S., Pregno, P., Bonifacio, M., Lunghi, F., Castagnetti, F., et al. (2019) · Blood · doi:10.1182/blood-2019-126767 · Cited by 6
Sigl, M., Spoerl, S., Schnittger, S., Meißner, J., Rummelt, C., Peschel, C., Duyster, J., Ho, A. D., & von Bubnoff, N. C. C. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.3 · Cited by 5
Remembrance of things past — discontinuation of second-generation TKI therapy for CML
Hughes, T. P., & Ross, D. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.11 · Cited by 5
Ohanian, M. N., Lin, T. L., Craig, M., Agrawal, A., Halka, K. G., Ashizawa, A. T., Cortes, J. E., & Roboz, G. J. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.tps7561 · Cited by 5
Mughal, T. I., Psaila, B., DeAngelo, D. J., Saglio, G. N., Etten, R. A. V., & Radich, J. P. (2021) · Haematologica · doi:10.3324/haematol.2020.267252 · Cited by 5
ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
Yan, D., Pomicter, A. D., O’Hare, T., & Deininger, M. W. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2270 · Cited by 4
Chronic myeloid leukemia: Global impact from a local laboratory
Radich, J. P. (2017) · Cancer · doi:10.1002/cncr.30776 · Cited by 3
Piwocka, K., Wolanin, K., Kusio-Kobiałka, M., & Podszywalow‐Bartnicka, P. (2011) · InTech eBooks · doi:10.5772/25780 · Cited by 2
Okabe, S., Tauchi, T., & Ohyashiki, K. (2010) · Blood · doi:10.1182/blood.v116.21.2136.2136 · Cited by 2
Alves, R. S., Gonçalves, A. C., Jorge, J., Marques, G., Ribeiro, A. B., Tenreiro, R., Coucelo, M., Diamond, J., Pereira, A., Freitas-Tavares, P., et al. (2019) · HemaSphere · doi:10.1097/01.hs9.0000562964.05114.68 · Cited by 2
Self-citationMDS: Recent progress in molecular pathogenesis and clinical aspects.
加藤, 奈. (2017) · PubMed · doi:10.11406/rinketsu.58.1941 · Cited by 2
When to consider allogeneic transplant for chronic myeloid leukemia
Egan, D. N., & Radich, J. P. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.85 · Cited by 1
Cited by
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 294
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
Apperley, J. F., Milojkovic, D., Cross, N. C. P., Hjorth-Hansen, H., Hochhaus, A., Kantarjian, H., Lipton, J. H., Malhotra, H., Niederwieser, D., Radich, J., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02664-w · Cited by 226
“[46].”
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Qin, Y., Han, S., Yu, Y., Ding, Q., Ran, M., Yang, M., Liu, Y., Li, Y., Lu, L., Liu, Y., et al. (2024) · Liver International · doi:10.1111/liv.15953 · Cited by 112
Rinaldi, I., & Winston, K. (2023) · Journal of Blood Medicine · doi:10.2147/jbm.s382090 · Cited by 128
Olverembatinib: First Approval
Dhillon, S. (2022) · Drugs · doi:10.1007/s40265-022-01680-9 · Cited by 71
Metadata
- Authors
- Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B.
- Affiliations
- Centro de Investigação em Meio Ambiente Genética e Oncobiologia (PT)
- Nottingham Trent University (GB)
- Hospital da Luz Lisboa, 1500-650 Lisbon, Portugal
- Cancer Research Center (CiC-IBMCC, CSIC/USAL/IBSAL, Consejo Superior de Investigaciones Científicas (CSIC), University of Salamanca (USAL) and Instituto de Investigación Biomédica de Salamanca (IBSAL)), 37007 Salamanca, Spain
- National and Kapodistrian University of Athens (GR)
- Laboratory of Oncobiology and Hematology, University Clinic of Hematology, Faculty of Medicine (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-09-26
- Volume
- 13
- Issue
- 19
- Pages
- 4820
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8508378
- OpenAlex
- W3204122798
- Cited by
- 204
- References
- 318
- Citations by year
- 2026: 42 · 2025: 51 · 2024: 38 · 2023: 46 · 2022: 27
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Nottingham Trent University's Institutional Repository (Nottingham Trent Repository) (acceptedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Estudo Geral (Universidad de Coimbra) (submittedVersion, cc-by)
- Funders
- Fundação para a Ciência e a Tecnologia (UIDB/04539/2020, UIDP/04539/2020)
- Ministerio de Ciencia e Innovación (PI18/00591)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- chronic myeloid leukemia, tyrosine kinase inhibitors, imatinib, drug resistance, BCR-ABL fusion gene, medication adherence, next-generation sequencing, digital PCR, artificial intelligence, mathematical modeling, resistance mechanisms, treatment options
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.